MX2020002336A - Composicion lipolitica que contiene derivados de fosfocolina. - Google Patents

Composicion lipolitica que contiene derivados de fosfocolina.

Info

Publication number
MX2020002336A
MX2020002336A MX2020002336A MX2020002336A MX2020002336A MX 2020002336 A MX2020002336 A MX 2020002336A MX 2020002336 A MX2020002336 A MX 2020002336A MX 2020002336 A MX2020002336 A MX 2020002336A MX 2020002336 A MX2020002336 A MX 2020002336A
Authority
MX
Mexico
Prior art keywords
composition
present
composition containing
phosphocholine derivatives
lipolytic activity
Prior art date
Application number
MX2020002336A
Other languages
English (en)
Inventor
Ji Hyun Moon
Seung Jun Lee
Dongkyu Park
Sang Yun Lee
Young Sub Song
Surin Kim
Joo Hwan Kim
Hana Lee
Seung Ho Ji
Original Assignee
Penmix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penmix Ltd filed Critical Penmix Ltd
Publication of MX2020002336A publication Critical patent/MX2020002336A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/84—Products or compounds obtained by lyophilisation, freeze-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

La presente invención proporciona una composición para lipólisis o para mejorar, inhibir o tratar depósitos de grasa localizados (LFD), que comprende ciertos derivados de fosfocolina o sal farmacéuticamente aceptable. La composición de la presente invención muestra una excelente actividad lipolítica así como una actividad lipolítica uniforme. Asimismo, la composición de la presente invención puede minimizar los efectos adversos tales como inflamación, necrosis de tejidos, etc. en el sitio de administración. Además, la composición de la presente invención tiene una excelente estabilidad de almacenamiento.
MX2020002336A 2017-11-03 2018-04-12 Composicion lipolitica que contiene derivados de fosfocolina. MX2020002336A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170145750A KR101865562B1 (ko) 2017-11-03 2017-11-03 포스포콜린 유도체를 포함하는 지방분해 조성물
PCT/KR2018/004296 WO2019088378A1 (en) 2017-11-03 2018-04-12 Lipolytic composition containing phosphocholine derivatives

Publications (1)

Publication Number Publication Date
MX2020002336A true MX2020002336A (es) 2020-07-20

Family

ID=62600323

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002336A MX2020002336A (es) 2017-11-03 2018-04-12 Composicion lipolitica que contiene derivados de fosfocolina.

Country Status (9)

Country Link
US (1) US10765688B2 (es)
EP (1) EP3641781A4 (es)
JP (1) JP7082189B2 (es)
KR (1) KR101865562B1 (es)
CN (1) CN111386120A (es)
BR (1) BR112020001556A2 (es)
CA (1) CA3022733A1 (es)
MX (1) MX2020002336A (es)
WO (1) WO2019088378A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101972588B1 (ko) 2018-07-31 2019-04-26 정채홍 지방분해 및 지방제거 시술 전처리용 조성물
KR102064864B1 (ko) * 2019-02-08 2020-01-10 (주)제테마 국소 주사용 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10349979B4 (de) * 2003-10-24 2006-05-18 Sanofi-Aventis Deutschland Gmbh Medikamentöse gezielte lokale Lipolyse
US20050143347A1 (en) 2003-12-22 2005-06-30 Aventis Pharma Deutschland Gmbh Medicinal lipolysis of accumulations of fat
AU2004308971A1 (en) * 2003-12-22 2005-07-14 Aventis Pharmaceuticals Inc. Injectable phosphatidylcholine preparations
DE10361067A1 (de) * 2003-12-22 2005-07-14 Aventis Pharma Deutschland Gmbh Medikamentöse Lipolyse von Fettansammlungen
US20050287199A1 (en) 2004-06-28 2005-12-29 Teresa Ann Denney Therapeutic micro nutrient composition for lipolysis and drug delivery
WO2009067182A2 (en) * 2007-11-16 2009-05-28 Baylor College Of Medicine Phospholipid compositions and uses thereof
CN101480402B (zh) * 2008-12-17 2012-05-23 北京世纪博康医药科技有限公司 一种环木菠萝烯醇阿魏酸酯药物组合物及其制备方法
US20130303466A1 (en) * 2010-10-19 2013-11-14 Elcelyx Therapeutics, Inc. Chemosensory Receptor Ligand-Based Therapies
WO2015198150A2 (en) * 2014-06-27 2015-12-30 Medy-Tox Inc. Methods and compositions of bile acids and salts for reduction of fat
CA2872279C (en) 2014-11-21 2018-06-12 Pankaj Modi Topical lipolysis compositions and methods
JP6426991B2 (ja) * 2014-12-02 2018-11-21 白鳥製薬株式会社 体脂肪減少促進剤
WO2017187426A1 (en) * 2016-04-29 2017-11-02 Aptamir Therapeutics, Inc. Inhibition of mir-22 mirna by apt-110

Also Published As

Publication number Publication date
JP2021501739A (ja) 2021-01-21
KR101865562B1 (ko) 2018-06-08
BR112020001556A2 (pt) 2020-07-21
EP3641781A1 (en) 2020-04-29
CA3022733A1 (en) 2019-05-03
US20190134068A1 (en) 2019-05-09
JP7082189B2 (ja) 2022-06-07
EP3641781A4 (en) 2021-03-10
US10765688B2 (en) 2020-09-08
CN111386120A (zh) 2020-07-07
WO2019088378A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
MX2016008201A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
MX2023007192A (es) Inhibidores de prmt5.
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
PH12016502355A1 (en) Pharmaceutical composition
MX2019012884A (es) Terapia de combinacion.
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
PH12016502353A1 (en) Pharmaceutical composition
TW201613577A (en) Pharmaceutical combinations
MX2023002325A (es) Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
WO2015095838A3 (en) Cancer treatments using combinations of mek type i and erk inhibitors
MX2021006156A (es) Compuestos utiles en la terapia para el vih.
CA2902116C (en) Pyrrolopyridine derivatives and their use as inhibitors of ssao activity
MX2020005841A (es) Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6.
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2021015543A (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo.
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
MX2019005104A (es) Composiciones de zinc-y-pga y métodos para tratar el cancer.
MX2020002336A (es) Composicion lipolitica que contiene derivados de fosfocolina.
PH12019501642A1 (en) Novel compounds and their use in the treatment of schistosomiasis
MX2019002121A (es) Tratamiento conjunto para tratar el cancer de pancreas.
MX2021005944A (es) Inhibidores de rip1.
EA201991069A1 (ru) Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом
SG10201708886RA (en) α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER